CD109 and glioblastoma: Through bioinformatics analysis and experiment verifications, we were the first to find and validated two lncRNA biomarkers, CD109-AS1 and LINC02447 involved in immune evasion, which will facilitate the development of immunotherapeutic targets for glioblastoma.